A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

3 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-23

Study Completion Date

2021-05-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study in participants with advanced cancer is to learn more about the safety of ramucirumab when given by injection under the skin (subcutaneous injection). The study will also measure how much ramucirumab gets into the bloodstream and how long it takes the body to get rid of it.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies

NCT04606381

Neoplasms

ACTIVE_NOT_RECRUITING PHASE1

A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001

NCT02096341

Malignant Solid Tumor Lymphomas

TERMINATED PHASE1

A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors

NCT01567163

Malignant Solid Tumor

COMPLETED PHASE2

A Study of LY3435151 in Participants With Solid Tumors

NCT04099277

Solid Tumor Triple-negative Breast Cancer Gastric Adenocarcinoma +6 more

TERMINATED PHASE1

Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)

NCT05514444

Advanced/Metastatic Solid Tumors Neoplasms

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Solid Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ramucirumab

Participants received starting dose of 700 milligram (mg) ramucirumab loading dose (LD) subcutaneously (SC) followed, a week later, by 350 mg ramucirumab maintenance dose (MD) administered SC once a week.

Group Type EXPERIMENTAL

Ramucirumab

Intervention Type DRUG

Administered SC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ramucirumab

Administered SC

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LY3009806

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have evaluable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).
* In the judgment of the investigator, be an appropriate candidate for experimental therapy and:

* For Cohort A only: Have exhausted all anticancer treatments with proven clinical benefit OR
* For Cohorts B and C only: Must have one of the three conditions below:

* Have exhausted all anti-cancer treatments with proven clinical benefit, OR
* Have hepatocellular carcinoma or gastric cancer who have received prior treatment, and where IV ramucirumab monotherapy is clinically acceptable treatment after progression OR
* Have a diagnosis for which IV ramucirumab in combination with additional anticancer therapy is clinically acceptable treatment
* Additionally, it must be clinically acceptable to delay initiation of the combination partner for 3 weeks from the initiation of ramucirumab dosing.
* Eastern Cooperative Oncology Group performance status score of 0 or 1.
* Have discontinued all previous treatments for cancer with adequate wash-out period and recovered from the acute effects of therapy.
* Have adequate hematologic, hepatic, and renal functions and electrolytes.
* Males and females of child-bearing potential must agree to use highly effective contraceptive methods during study treatment and for at least 84 days/12 weeks following the last dose of study drug.

Exclusion Criteria

* Have uncontrolled hypertension defined as systolic blood pressure (BP) \>150 mmHg or diastolic BP \>90 mmHg despite standard medical management.
* Have significant bleeding disorders or experienced Grade 3/4 gastrointestinal (GI) bleeding within 3 months prior to enrollment.
* Have hepatic impairment (such as severe liver cirrhosis Child-Pugh B \[or worse\], cirrhosis with a history of hepatic encephalopathy, clinically meaningful ascites requiring ongoing treatment with diuretics and/or paracentesis, or history of hepatorenal syndrome).
* Have experienced any arterial thromboembolic events (ATEs), including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, ≤6 months prior to randomization.
* The participant has clinically relevant congestive heart failure (CHF; New York Heart Association \[NYHA\] Grade ≥2) or symptomatic or poorly controlled cardiac arrhythmia.
* Have symptomatic central nervous system (CNS) metastases. Screening is not required.
* Have history of GI perforation and/or fistula within 6 months prior to enrollment.
* Have an active uncontrolled systemic bacterial, viral, or fungal infection or serious ongoing uncontrolled intercurrent illness.
* Have a serious or non-healing wound, ulcer, or bone fracture within 4 weeks prior to enrollment.
* Have received IV ramucirumab in the past.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No